Aripiprazole Lauroxil for Preventing Psychotic Relapse After an Initial Schizophrenia Episode

PHASE4TerminatedINTERVENTIONAL
Enrollment

15

Participants

Timeline

Start Date

December 16, 2019

Primary Completion Date

October 1, 2022

Study Completion Date

October 1, 2022

Conditions
SchizophreniaSchizoaffective Disorder, Depressive TypeSchizophreniform Disorder
Interventions
DRUG

Aripiprazole Lauroxil

12 month longitudinal aripiprazole lauroxil treatment and assessment follow-through

DRUG

ARI-ORAL

oral aripiprazole

DRUG

AL-NCD

Aripiprazole Lauroxil 675 MG/2.4 ML Intramuscular Suspension, Extended Release

Trial Locations (1)

90095

University of California, Los Angeles, Los Angeles

Sponsors

Collaborators (1)

All Listed Sponsors
collaborator

Alkermes, Inc.

INDUSTRY

lead

University of California, Los Angeles

OTHER

NCT04203056 - Aripiprazole Lauroxil for Preventing Psychotic Relapse After an Initial Schizophrenia Episode | Biotech Hunter | Biotech Hunter